Home
Resources
Publications
Retrospective Evaluation of Toceranib Phosphate (Palladia®) Use in the Treatment of Gastrointestinal Stromal Tumors of Dogs

Retrospective Evaluation of Toceranib Phosphate (Palladia®) Use in the Treatment of Gastrointestinal Stromal Tumors of Dogs

Erika P Berger, Chad M Johannes, Albert E Jergens, Karin Allenspach, Barbara E Powers, Yingzhou Du, Jonathan P Mochel, Leslie E Fox, Margaret L Musser

J Vet Intern Med. 2018 Nov;32(6):2045-2053.

PMID: 30307656

Abstract:

Background:
Gastrointestinal stromal tumors (GISTs) are uncommon intestinal neoplasms in the dog. Literature regarding adjunctive therapy for GISTs in dogs is sparse. High-risk GISTs in humans respond to tyrosine kinase inhibition in the adjuvant setting.
Objectives:
To review cases of toceranib phosphate use in dogs with GISTs and provide initial assessment of possible biological activity. A secondary aim was to evaluate patient and tumor characteristics for possible prognostic value.
Animals:
Twenty-seven dogs with confirmed GISTs based on histopathology and immunohistochemistry treated with toceranib.
Methods:
Retrospective study in which cases of toceranib use in dogs with GIST were solicited using the American College of Veterinary Internal Medicine Oncology and Small Animal Internal Medicine listservs.
Results:
Five of 7 dogs with gross disease experienced clinical benefit (71%; 3 complete responses, 1 partial response, 1 stable disease). These included 2 dogs with durable responses after toceranib discontinuation. Median progression-free interval (PFI) in dogs with gross disease was 110 weeks (range, 36-155 weeks). Median PFI in dogs with microscopic disease was 67 weeks (range, 9-257 weeks). Metastasis at diagnosis (P = 0.04) and high mitotic index (P < 0.001) were associated with shorter PFI in toceranib-treated dogs.
Conclusions and clinical importance:
Biological activity of toceranib is evident in dogs with gross disease. Metastasis of GIST at diagnosis, as well as high tumor mitotic index, was associated with shorter PFI in toceranib-treated dogs. Larger studies are needed to define postsurgical risk and refine the use of toceranib in dogs with gross and microscopic GIST.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP356068945	Toceranib		356068-94-5	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: